Obesity – Talk Bio

Novo Nordisk Ends Cell Therapy Research Amid Major Restructuring

1 week ago talkbio0Tagged cancellations, Cell Therapy, cost-cutting, Diabetes, Novo Nordisk, Obesity, Partnership, R&D strategy, restructuring

Novo Nordisk; cell therapy; restructuring; job cuts; diabetes; cost-cutting; R&D strategy; biotech; obesity; partnership cancellations

Eli Lilly to Invest Over $1 Billion to Expand Manufacturing Footprint in India

2 weeks ago talkbio0Tagged Alzheimer 's, Autoimmune, contract manufacturing, Diabetes, eli lilly, expansion, Hyderabad, India, Malignant Neoplasms, Manufacturing, Obesity

Eli Lilly; India; manufacturing expansion; contract manufacturing; Hyderabad; pharmaceuticals; obesity; diabetes; Alzheimer’s; cancer; autoimmune

Novo Nordisk Terminates $598M Heart Failure Cell Therapy Collaboration with Heartseed Amid Major Restructuring

3 weeks ago talkbio0Tagged Biotechnology, Cardiospermum grandiflorum, Cell Therapy, Collaboration termination, Diabetes, Heart failure, HS-001, Maziar Mike Doustdar, Nordisk, Obesity, strategic restructuring

Novo Nordisk; Heartseed; heart failure; cell therapy; HS-001; collaboration termination; strategic restructuring; Maziar Mike Doustdar; diabetes; obesity; biotechnology

Metsera’s New Obesity Data Raises Efficacy Profile, Key Side Effect Questions for Pfizer After Acquisition

3 weeks ago talkbio0Tagged aspects of adverse effects, Effectiveness, Glucagon-Like Peptide 1, MET-097i, Metsera, Obesity, Pfizer, Pfizer acquisition, Phase 2 trial, Weight Loss

Metsera; Pfizer; obesity drug; MET-097i; GLP-1; side effects; efficacy; Phase 2 trial; weight loss; Pfizer acquisition

Eli Lilly Withdraws $1.9B Phase 2b Obesity Trial Before Launching Enrollment

4 weeks ago talkbio0Tagged bimagrumab, Clinical Trials, Diabetes Mellitus, Non-Insulin-Dependent, Eli, Eli Lilly, Obesity, regulatory strategy, tirzepatide, Trial Termination, Zepbound

Eli Lilly; obesity drug; tirzepatide; bimagrumab; trial termination; phase 2b; Zepbound; type 2 diabetes; clinical trial; regulatory strategy

Pfizer’s $4.9B Metsera Deal Signals More Pharma M&A in Booming Obesity Drug Market

4 weeks ago talkbio0Tagged biotech acquisition, Glucagon-Like Peptide 1, late-stage clinical development, M&A, Metsera, Obesity, Pfizer, Pharma, pharmaceutical market, Weight Loss

Pfizer; Metsera; obesity drugs; weight loss; pharma M&A; GLP-1; biotech acquisition; pharmaceutical market; late-stage clinical development

Eli Lilly Invests $6.5 Billion in Texas Facility to Manufacture Obesity Pill

4 weeks ago talkbio0Tagged alpha 1-antitrypsin, Artificial Intelligence, Automation, Contraceptives, Oral, eli lilly, Obesity, orforglipron, pharmaceutical manufacturing, Supply Chain Resilience, Surgical construction, Texas Facility

Eli Lilly; Texas facility; obesity pill; orforglipron; pharmaceutical manufacturing; API; AI automation; supply chain resilience; job creation

Roche’s Top Three Ambition in Obesity Not Dependent on a Single Megablockbuster

4 weeks ago talkbio0Tagged cardiometabolic care, Diagnostics, digital health, Ecosystem, Obesity, Portfolio diversification, Roche (company), Weight-Loss Agents

Roche; obesity strategy; ecosystem approach; pharmaceuticals; diagnostics; digital health; cardiometabolic care; portfolio diversification; weight-loss drugs